For this reason, targeting VEGF and other components to normalize tumor vasculature has emerged as a promising therapeutic approach beyond cancer, and VEGF also plays a critical role in the pathogenesis of AMD, where overgrowth of blood vessels in the eye leads to vision loss, thereby VEGF-targeting antibodies such as ranibizumab and bevacizumab have demonstrated significant therapeutic efficacy in ADM treatment [14]. The gene discussed is VEGFA; the disease is age-related macular degeneration.